Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Termination
Details : BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).
Brand Name : Zebinix
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 17, 2021
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Termination
LOOKING FOR A SUPPLIER?